Clinical trial · Interventional
Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC
Neoadjuvant Immunochemotherapy Versus Chemoradiotherapy in Locally Advanced Esophageal Cancer: A Real-World Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This retrospective real-world study aimed to compare neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT) followed by esophagectomy in patients with locally advanced esophageal squamous cell carcinoma (ESCC). A total of 203 consecutive patients treated at Sichuan Cancer Hospital between March 2018 and March 2022 were analyzed (NICT: 59; NCRT: 144). The primary endpoints were overall survival (OS) and disease-free survival (DFS); secondary endpoints included pathological complete response (pCR), tumor regression grade (TRG), and R0 resection rate. After inverse probability of treatment weighting adjustment, baseline characteristics were balanced between groups. Both groups achieved comparable long-term OS and DFS, while NCRT showed higher rates of local pathological response. Exploratory subgroup analysis suggested that patients achieving pCR after NICT might have superior survival outcomes. The study indicates that NICT provides similar long-term survival compared to NCRT and may offer immunologic advantages for selected responders, warranting further validation in prospective multicenter trials.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Squamous Cell Carcinoma (ESCC) | Esophageal Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neoadjuvant Chemoradiotherapy | Drug | — | UNRESOLVED |
| Neoadjuvant immunochemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- NICT group
- interventionNames
- Drug: Neoadjuvant immunochemotherapy
- type
- ACTIVE_COMPARATOR
- label
- NCRT group
- interventionNames
- Drug: Neoadjuvant Chemoradiotherapy
Primary outcomes (2)
- measure
- Overall Survival (OS)
- timeFrame
- 5 years
- description
- Time from first treatment to death from any cause or last follow-up.
- measure
- Disease-Free Survival (DFS)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18-80 years * Histologically confirmed thoracic ESCC * Clinical stage cT1N+M0 or cT2-4aN0-3M0 * Received neoadjuvant therapy (immunochemotherapy or chemoradiotherapy) followed by esophagectomy Exclusion Criteria: * History of other malignancies * Did not complete neoadjuvant therapy or required salvage surgery * Incomplete baseline or follow-up data
References
Publications (0)
Data not yet available